source
- Roche halts development of Huntington’s disease drug tominersen after ten years of trialsRoche announced it is stopping work on tominersen, its experimental therapy for Huntington’s disease. The decision follows a Phase 2 study in which the drug performed no better than placebo. The c…
- UK regulator advises stopping reimbursement for Amgen's lung cancer drug Lumakras for new patientsThe National Institute for Health and Care Excellence (NICE) in the United Kingdom released draft guidance recommending that government reimbursement for Amgen’s lung cancer therapy Lumakras be dis…